Author: Bob Kohut

Bob Kohut
Bob Kohut

Bob Kohut has been writing about finance for more than 30 years. As an active trader he brings a unique perspective to share market trading and investing issues.

feedback or questions?

Include your name, the article headline and your message.

EMAIL THE AUTHOR

FOLLOW ELSEWHERE

Recent and archived work by Bob Kohut for The Bull:

Can Hydrogen Recapture the Title of Fuel of the Future?

Hydrogen gas can trace its discovery back to 1776, with the first flight of a hydrogen filled “hot air” balloon in 1783. Science fiction novelist Jules Verne picturing its potential use as a transportation fuel in 1874. Verne’s dream morphed into reality with the advent of hydrogen powered balloons in the mid-1800’s and hydrogen airships…

Disruptive ASX Stocks Withstanding the Test of Time

Nervous investors everywhere watch the daily movements of US stocks as likely bell weathers for stock performance in their own markets. Through mid-May, the US lead followed in the majority of global markets continues to be bleak and tumultuous – down day after down day occasionally interrupted by rallies that quickly recede. In the midst…

Small Cap Biotechs Making News

In 2017 the ASX published a report prepared in conjunction with Australia’s primary life science organisation, AusBiotech, entitled Guide to Life Sciences Investing. The ASX Healthcare Sector is broadly divided into two subsectors – Health Care Equipment and Services and Pharmaceuticals, Biotechnology, and Life Sciences. Listcorp.com – a site devoted to allowing investors access to…

Will the WAAX Stocks Come Back?

Investors in both the United States and Australia have turned on former “market darlings” in both countries with a vengeance. When market participants couldn’t buy sector leaders fast enough, someone coined the acronym for the big players in the US – the FANG stocks (Facebook—now Meta, Apple, Netflix, and Google – now Alphabet. From Yahoo…

Is It Time to Buy Iron Ore Miners?

In February of 2011, the price of iron ore hit an all-time high of USD$187 dmt (dry metric tonne). Fueling the price explosion was the multi-year campaign by the Chinese government to modernise the country. Expanding a country’s industrial production capacity and creating urban areas to house needed employees requires massive infrastructure development, from roads,…

Will Cobalt Remain an EV Battery Staple?

Speculation about the potential explosion in the demand for electric vehicles (EVs) in the midst of the last decade saw the prices of some of the metals needed to produce the batteries capable of powering those vehicles more than doubling by 2018. Lithium, nickel, and cobalt led the charge, but when the speculation appeared to…

The Lithium Juggernaut Powers On

Retail investors with a liking for commodity stocks should know the inherent risk of buying into a booming market. When the demand for steel seemed insatiable, Aussie investors feasted on iron ore stocks, especially the junior miners with more room to run. Steel demand is driven by construction projects, with the proliferation of building projects…

52 Week Highs with Tailwinds

Members of that bold and confident group of investors labeled as “stock-pickers” have multiple choices for hunting for targets. While investors with high risk aversion seek the relative safety of fixed choice or exchange traded/mutual funds investing, those willing to accept the risks know the potential benefits of picking their own stocks far outweigh the…

Upcoming ASX IPOs with Trader-Related Business Models

In the calendar year 2021 the ASX IPO market saw listings more than doubling from the sixty-seven in FY 2020 to 163. As newcomers to share market investing quickly learn, all prospective listees on the ASX must publish a prospectus to accompany their submission for listing. No matter the business model, every IPO Prospectus released…

Under the Radar Biotechnology Stocks Approaching Clinical Trials

Investors with high risk appetites gravitate towards the biotechnology sub-sector of healthcare stocks where clinical trials sometimes yield significant share price movement. Depending on the treatment and the market size of the affected population, positive announcements regarding the progress of the trials can reward investors handsomely, at least in the short term. The risk is…